WuXi Advanced Therapies Inc. (WuXi ATU) – a wholly owned subsidiary of WuXi AppTec – today announced the opening of its new process development and commercial manufacturing facility in Lin-gang, Shanghai. WuXi ATU is a leading Contract, Testing, Development and Manufacturing Organization (CTDMO) headquartered in Philadelphia. As its fourth manufacturing site worldwide, the new facility will supplement WuXi ATU’s global footprint and will further join with other sites in the United States, United Kingdom and China to enable global customers with enhanced capacity and efficient services.
The Lin-gang facility offers integrated development, manufacturing, and testing services for viral vectors and cell therapies. It contains more than 200 independent suites and six complete production lines, including an independent liquid distribution center and independent GMP standard sterile filling isolator. These resources will strengthen WuXi ATU’s operations worldwide, offering customers greater flexibility and speed in the delivery of viral vectors and cell therapies.
The Lin-gang facility’s opening follows a major expansion of WuXi ATU’s Philadelphia Navy Yard campus in 2020 that tripled its advanced testing capacity and provided much needed services for clients globally.
“Cell and gene therapies play a critical role in helping treat and prevent many severe and rare diseases, which is why WuXi ATU is committed to growing our comprehensive one-stop service platform specifically dedicated to the gene and cell therapy field,” said Dr. David Chang, Chief Executive Officer of WuXi ATU. “By expanding our global footprint, we will provide enhanced cell and gene therapy manufacturing services for our customers worldwide and better enable them to deliver more effective and accessible advanced therapies to patients.”
As a CTDMO with operations globally, WuXi ATU’s unique business model integrates powerful testing capabilities with its advanced therapies’ process development and manufacturing platforms such as TESSA technology for AAV manufacturing and XLenti stable solutions for lentiviral manufacturing, so that all assay development, biosafety, viral clearance and product release testing can be carried out in house, enabling customers to shorten the timeline for the approval of advanced therapies.
Check Out The New Martech Cube Podcast. For more such updates, follow us on Google News Martech News